Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
J Clin Microbiol. 2010 Nov;48(11):4003-9. doi: 10.1128/JCM.00812-10. Epub 2010 Sep 1.
The current study describes the development of a unique real-time PCR assay for the detection of mutations conferring drug resistance in Mycobacterium tuberculosis. The rifampicin resistance determinant region (RRDR) of rpoB and specific regions of katG and the inhA promoter were targeted for the detection of rifampin (RIF) and isoniazid (INH) resistance, respectively. Additionally, this assay was multiplexed to discriminate Mycobacterium tuberculosis complex (MTC) strains from nontuberculous Mycobacteria (NTM) strains by targeting the IS6110 insertion element. High-resolution melting (HRM) analysis following real-time PCR was used to identify M. tuberculosis strains containing mutations at the targeted loci, and locked nucleic acid (LNA) probes were used to enhance the detection of strains containing specific single-nucleotide polymorphism (SNP) transversion mutations. This method was used to screen 252 M. tuberculosis clinical isolates, including 154 RIF-resistant strains and 174 INH-resistant strains based on the agar proportion method of drug susceptibility testing (DST). Of the 154 RIF-resistant strains, 148 were also resistant to INH and therefore classified as multidrug resistant (MDR). The assay demonstrated sensitivity and specificity of 91% and 98%, respectively, for the detection of RIF resistance and 87% and 100% for the detection of INH resistance. Overall, this assay showed a sensitivity of 85% and a specificity of 98% for the detection of MDR strains. This method provides a rapid, robust, and inexpensive way to detect the dominant mutations known to confer MDR in M. tuberculosis strains and offers several advantages over current molecular and culture-based techniques.
本研究描述了一种独特的实时 PCR 检测方法,用于检测结核分枝杆菌中导致耐药性的突变。该方法针对 rpoB 的利福平耐药决定区(RRDR)和 katG 及 inhA 启动子的特定区域进行检测,分别用于检测利福平(RIF)和异烟肼(INH)耐药性。此外,该检测方法还通过靶向 IS6110 插入元件进行了多重化,以区分结核分枝杆菌复合群(MTC)菌株和非结核分枝杆菌(NTM)菌株。实时 PCR 后进行高分辨率熔解(HRM)分析,以鉴定含有靶向位点突变的结核分枝杆菌菌株,并使用锁核酸(LNA)探针增强对含有特定单核苷酸多态性(SNP)颠换突变的菌株的检测。该方法用于筛选 252 株结核分枝杆菌临床分离株,包括基于琼脂比例法药物敏感性试验(DST)的 154 株 RIF 耐药菌株和 174 株 INH 耐药菌株。在 154 株 RIF 耐药菌株中,有 148 株也对 INH 耐药,因此被归类为耐多药(MDR)。该检测方法对 RIF 耐药性的检测灵敏度和特异性分别为 91%和 98%,对 INH 耐药性的检测灵敏度和特异性分别为 87%和 100%。总的来说,该检测方法对 MDR 菌株的检测灵敏度为 85%,特异性为 98%。该方法为检测结核分枝杆菌中已知导致 MDR 的主要突变提供了一种快速、稳健且廉价的方法,与当前的分子和基于培养的技术相比具有多项优势。